LLYX

LLYX remains in a Stage 2 advancing regime with a bullish medium-term bias supported by a Higher Highs & Higher Lows structure and rising EMAs. The recent pullback is pulling price into the 9/21 EMA zone, and short-term timing is unfavorable for immediate entry. We prefer to stalk deeper pullbacks into the rising EMA zone or onto the 50-day SMA as it holds. A decisive breakdown below the rising 50-day SMA and the mid-July higher-low would invalidate the bullish stance.

• ↑2× leverage doubles gains when Eli Lilly stock rallies
• ↑Eli Lilly’s revenue climbed 9% YoY to $30.7B in 2024
• ↓2× leverage doubles losses during Eli Lilly stock downturns